Chaetominine is a cytotoxic alkaloid that has been demonstrated to promote apoptotic cell death in human leukemia K562 cells. In the present study, chaetominine inhibited K562 (IC 50 34 nM) and SW1116 (IC 50 46 nM) cell growth. However, it remains unclear whether the inhibition of cell growth is associated with the cell cycle. To assess this potential relationship, the effect of chaetominine on the cell cycle of K562 and SW1116 cells was examined. Chaetominine treatment caused cell apoptosis and G 1 -phase arrest in SW1116 cells. Conversely, K562 cells underwent S-phase arrest according to flow cytometric analysis. The present study also aimed to elucidate the molecular mechanisms underpinning cell cycle regulation following the incubation of the associated cells with chaetominine. Western blot and reverse transcription-quantitative polymerase chain reaction analyses suggested that chaetominine treatment facilitated the expression of p53, p21, checkpoint kinase 2 (Chk2) and phosphorylated ataxia telangiectasia mutated (p-ATM) and caused a reduction in the mRNA levels of cyclin E and cyclin-dependent kinases (CDKs) 2 and 4. These results suggest that chaetominine may be involved in the regulation of p53/p21 and ATM and Rad3-related (ATM)/Chk2 signaling in SW1116 cells. Previous studies have demonstrated that these signaling pathways are responsible for G 1 -phase arrest. Results of the present study demonstrated that the expression of p-ATR and Chk1 were increased in K562 cells. Additionally, cdc25A levels were decreased, while protein and gene expression levels of cyclin A and CDK2 were repressed. These results elucidated the role of chaetominine in in the regulation of ATR/cdc25A/Chk1 expression in K562 cells. These proteins are thus important determinants in the initiation of S-phase arrest. These data support the hypothesis that chaetominine is a potential anti-cancer therapeutic agent that targets the cell cycle.
Introduction
Natural products and their respective metabolites are valuable resources that have enabled the detection of novel chemotherapeutic agents (1) . Among these, alkaloids have demonstrated promising anti-cancer effects. These compounds have also been revealed to elicit effects on a variety of different targets, including regulators associated with cell cycle progression, cell apoptosis and drug resistance inhibition (2) . Chaetominine is an alkaloid (Fig. 1A ) isolated from the metabolites of an endophytic fungus, Aspergillus fumigatus CY018 (3) . A previous study demonstrated that chaetominine may be lethal to human leukemia K562 cells, with its effects being mediated through the mitochondrial apoptosis pathway (4) . Previous studies have indicated that similar compounds have the capacity to inhibit cancer cell growth by inducing cell apoptosis and/or cell cycle arrest (4) (5) (6) .
Efficient regulation of the cell cycle is crucial to the process of cell survival and involves the prevention of uncontrolled cell division alongside the detection and repair of genetic damage associated with tumorigenesis (7) . Checkpoints are pivotal components of the cell cycle regulative machinery and are governed by effector kinases, including ataxia telangiectasia mutated (ATM) and ATM and Rad3-related (ATR) proteins. The predominant downstream transducers of checkpoints include checkpoint kinase 1 and checkpoint kinase 2 (Chk1 and Chk2) as well as p53 (8) . The activation of the p53-p21 cascade in the ATM/Chk2/p53 signaling pathway facilitates the induction of G 1 -phase arrest (7) . Conversely, S-phase arrest is primarily triggered by multiple pathways that involve the inhibition of cell division cycle 25A (cdc25A). These pathways transmit checkpoint signals to cyclin-dependent kinases (CDKs), which form complexes with cyclins, resulting in cell cycle arrest (9) . CDK2 and CDK4 are responsible for G 1 /S transitions during the cell cycle. These events occur following the interaction of kinases with their respective cyclin complex subunits. The binding of cyclin E with G 1 -phase CDK2
Chaetominine induces cell cycle arrest in human leukemia K562 and colon cancer SW1116 cells JINGYUN YAO 1, 2 , JIANBO XIAO 3 , XING WEI 1,2 and YANHUA LU promotes the transition of G 1 -to S-phase, while cyclin A is required to activate CDK2 for progression through the S-phase (9, 10) . Once cell cycle arrest occurs, related signaling pathways are activated, leading to the initiation of the cell death program. This results in the inhibition of cancer cell growth. Accordingly, biomedical studies are focused on the identification and evaluation of novel inhibitors of protein kinases that are restricted to the cell cycle (2) . Chaetominine has been demonstrated to exhibit toxic effects against the human leukemia cell line K562 and the human colon cancer cell line SW1116 (11) . However, the molecular mechanisms that underpin the cytotoxic effects of chaetominine are yet to be elucidated fully. Following a previous study that observed the cytotoxic and apoptotic effects of K562 cells (4), the present study hypothesized that chaetominine may alter cell cycle progression in these two cancer cell lines. The apoptotic effects induced by chaetominine on SW1116 cells and cell cycle regulation in SW1116 and K562 cells following treatment with chaetominine were also assessed. The inhibitory effects on cell growth promoted by chaetominine are likely to vary depending on the cell type that is exposed to the compound. Additionally, the molecular mechanisms involved in chaetominine-induced cell cycle arrest in K562 and SW1116 cells were elucidated in the present study.
Materials and methods

Reagents.
Chaetominine was extracted from a liquid culture of A. fumigatus CY018. The purity of the preparation was determined to be 99.8% (4) . MTT was purchased from Sigma-Aldrich; Merck KGaA (Darmstadt, Germany).
Cell culture. Human leukemia and colon cancer cell lines, K562 and SW1116, were obtained from the Shanghai Institute for Biological Sciences (Shanghai, China). K562 cells were cultured in RPMI-1640 (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.) and SW1116 cells were cultured in Dulbecco's modified Eagle's medium (Gibco; Thermo Fisher Scientific, Inc.) containing 10% FBS. Cells were maintained for 1-2 days at 37˚C in a humidified incubator containing 5% CO 2 .
Cell viability assay. The effect of chaetominine on cancer cell viability was evaluated using a MTT assay. Chaetominine was dissolved in 1 ml dimethyl sulfoxide at a concentration of 1 mM (DMSO; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) for the following assays. Cells were seeded in 96-well plates at a concentration of 10 5 cells/ml. All cell lines were incubated with 100, 50, 25, 12.5, 6.25 or 0 nM chaetominine for 48 h, and 1/10,000 (v/v, 0.01 µl DMSO in 100 µl reaction system) DMSO was used instead of chaetominine for the control groups. Each well was supplemented with 20 µl MTT (5 mg/ml, diluted in RPMI-1640 medium to dissolve the purple formazan) and incubated for a further 4 h prior to testing. The absorbance was subsequently measured using a microplate reader (SpectraMax ® i3; Molecular Devices LLC, Sunnyvale, CA, USA) at an experimental wavelength of 570 nm and a reference wavelength of 630 nm. The half maximal inhibitory concentration (IC 50 ) values were calculated using GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA).
Annexin V-Fluorescein isothiocyanate (FITC)/propidium iodide (PI) staining. Apoptotic rate was measured using flow cytometry. Cells were treated with 100, 50, 25 and 0 nM chaetominine for 24 h in 6-well plates. Cells were then harvested with PBS and incubated with Annexin V-FITC at 20-25˚C for 10 min in the dark using an Annexin V-FITC/PI kit (Nanjing Keygen Biotech Co., Ltd., Nanjing, China). Cells were subsequently suspended in a mixture of Annexin V and PI buffer following centrifugation at room temperature, at a Western blot assay. Whole lysates were prepared with cell lysis buffer (Biotech Well, Shanghai, China) following incubation with 40, 20, 10 or 0 nM chaetominine for 24 h. Lysates were subsequently washed with PBS and protein concentrations were determined using a bicinchoninic acid protein assay kit (Pierce; Thermo Fisher Scientific, Inc.). Protein samples (20 µg/lane) containing 0.01% bromophenol blue were separated using 10% SDS-PAGE and were subsequently transferred onto polyvinylidene difluoride membranes (EMD Millipore, Billerica, MA, USA). The PVDF membranes were blocked at room temperature for 2 h with 5% bovine serum albumin (diluted in TBS-Tween-20; TBS-T) and incubated overnight with the appropriate primary antibody (diluted with blocking buffer) at 4˚C. Primary antibodies against ATM (dilution, 1:500; cat. no. SC-377239), phosphorylated (p)-ATM (Ser1981; dilution, 1:500; cat. no. SC-47739), Chk1 (dilution, 1:200; cat. no. SC-8408), Chk2 (dilution, 1:200; cat. no. SC-5278), p53 (dilution, 1:200; cat. no. SC-126), p21 (dilution, 1:200; cat. no. SC-469), GAPDH (dilution, 1:1,000; cat. no. SC-69778) and β-actin (dilution, 1:1,000; cat. no. SC-47778) were obtained from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). ATR (dilution, 1:1,000; cat. no. 2790), p-ATR (Ser428; dilution, 1:1,000; cat. no. 2853), Cdc25A (dilution, 1:1,000; cat. no. 3652), cyclin A (dilution, 1:1,000, cat. no. 4656) and CDK2 (dilution, 1:1,000; cat. no. 2546) primary antibodies were obtained from Cell Signaling Technology, Inc. (Danvers, MA, USA). Horseradish peroxidase-conjugated goat anti-mouse (dilution, 1:1,000; cat. no. A0216) and goat anti rabbit (dilution, 1:1,000; cat. no. A0208) secondary IgG (H+L) antibodies were purchased from Beyotime Institute of Biotechnology (Haimen, China). Following three sequential TBS-T washes, the membranes were incubated overnight with horseradish peroxidase-labeled secondary antibodies at 4˚C. An enhanced chemiluminescence kit (Biotech Well) was used to visualize the immunoreactions. Protein levels were determined following the detection of chemiluminescent signals. The signals were quantified using Quantity One v4.62 software (Bio-Rad Laboratories Inc., Hercules, CA, USA).
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Total RNA was extracted using a Total RNA Extraction kit (Nanjing Keygen Biotech Co., Ltd.). RNA samples were quantified using UV spectrophotometry at a wavelength of 260 nm. Reverse transcription into cDNA was performed using a PrimeScript™ RT reagent kit (Takara Biotechnology Co., Ltd, Dalian, China) with 500 ng total RNA. cDNA was subsequently utilized for PCR analysis. The qPCR reaction was conducted using SYBR ® Premix Ex Taq™ II (Takara Biotechnology Co., Ltd.) on a CFX96 Touch™ PCR Detection system (Bio-Rad Laboratories, Inc.). The conditions for PCR amplification were as follows: 40 cycles of initial duration at 94˚C for 30 sec, annealing at 60˚C for 30 sec and extension at 72˚C for 1 min. The primer sequences used were as follows: Cyclin A, 5'-TCC ATG TCA GTG CTG AGA GGA-3' (forward), 5'-GAA GGT CCA TGA GAC AAG GC-3' (reverse); CDK2, 5'-GCT TTC TGC CAT TCT CAT CG-3' (forward), 5'-GTC CCC AGA GTC CGA AAG AT-3' (reverse); cyclin E, 5'-TTT CTT GAG CAA CAC CCT-3' (forward), 5'-GTC ACA TAC GCA AAC TGG-3' (reverse); CDK4, 5'-CTG AGA ATG GCT ACC TCT CGA TAT G-3' (forward), 5'-AGA GTG TAA CAA CCA CGG GTG TAA G-3' (reverse); glyceraldehyde-3-phophate dehydrogenase (GAPDH), 5'-CAA CGG ATT TGG TCG TAT T-3' (forward), 5'-CAC AGT CTT CTG GGT GGC-3' (reverse). The mRNA level associated with each gene was normalized to that of the internal control, GAPDH, and was quantified using the -2 ΔΔCq method (12) .
Statistical analysis. Data were analyzed using Graphpad Prism 5 (Graphpad Software Inc., La Jolla, CA, USA) and are expressed as the mean ± standard deviation. Group comparisons of experimental data were performed using a one-way analysis of variance with post-hoc Newman-Keuls tests. P<0.05 was considered to indicate a statistically significant result.
Results
Chaetominine inhibits the cell viability of K562 and SW1116 cells. The cytotoxic effects of chaetominine on K562 and SW1116 cells were analyzed using an MTT assay. The IC 50 values for chaetominine in K562 and SW116 cells were 33.7±0.2 and 45.9±3.4 nM, respectively. The results demonstrated that chaetominine inhibited K562 and SW1116 cell viability at concentrations of 6.25, 12.5, 25, 50 and 100 nM (Fig. 1B) . These data were consistent with those reported in a previous study (11) .
Chaetominine induces apoptosis of SW1116 cells.
A previous study demonstrated that chaetominine induces apoptotic cell death in K562 cells (4) . Following these results, the present study utilized flow cytometry to assess whether chaetominine induces cell apoptosis in SW1116 cells. The apoptosis rates were determined using dual staining with Annexin V-FITC and PI. It was revealed that chaetominine significantly increased early and late apoptosis rates compared with the control group ( Fig. 2A) . The total apoptosis rate gradually increased from 6.4% in the control group to 16.4, 35.6 and 60.0% in cells incubated with 25, 50 and 100 nM chaetominine, respectively. These results suggested that chaetominine induces apoptotic cell death in SW1116 cells. (Fig. 2B ). In addition, chaetominine caused an increase in the number of S-phase K562 cells ( Fig. 3A; control, 25.26%; 10 nM, 36.14%; 20 nM, 43.54%; and 40 nM, 49.5%). This occurred in a dose-dependent manner. These results indicated that cell cycle arrest was a mechanism used by chaetominine to induce cytotoxicity in K562 and SW1116 cells. In addition, chaetominine treatment resulted in cell cycle arrest at the G 1 stage (SW1116) or S stage (K562) depending on which cell type was analyzed.
C h a e t o m i n i n e i n f l u e n c e s t h e e x p re s s i o n o f
ATM/Chk2/p53/p21 in SW1116 cells. In order to elucidate the molecular mechanism associated with G 1 -phase arrest exhibited by chaetominine treated SW1116 cells, the signaling proteins involved in the regulation cascade of the cell cycle were evaluated using western blotting. p53 induces cell cycle arrest at the G 1 -stage, resulting in the activation of p21, which promotes the inhibition of CDKs (2). The results demonstrated that the expression of p53 and p21 were upregulated in SW1116 cells following incubation with chaetominine (Fig. 3B) . This upregulation occurred in a time-dependent manner. The association between ATM/Chk2 and chaetominine was assessed. It was demonstrated that chaetominine increased the phosphorylation and accumulation of ATM and Chk2, respectively. However, treatment did not notably affect the expression of ATM (Fig. 4A) . The significant phosphorylation of ATM is accompanied by the upregulation of Chk2 expression and demonstrates that pATM is associated with Chk1 regulation, which assists in checkpoint regulation (13) . It was determined that chaetominine modulates the ATM/Chk2/p53/p21 signaling pathway, which is an important effector of G 1 -phase arrest (7, 13) .
Chaetominine alters the expression of ATR/Chk1/cdc25A in K562 cells. The mechanism by which chaetominine induces S-phase arrest in K562 cells was further assessed. Western blotting was utilized to determine if the effects elicited by chaetominine were associated with the alteration of cell-cycle regulatory kinases. Cyclin A is a critical component involved in the regulation of cell cycle progression, which becomes functionally active once bound to CDK2. This association subsequently allows cells to continue through the S-phase (14) . Based on previous data, the present study determined the expression levels of cyclin A, CDK2 and upstream proteins including cdc25A, Chk1/2 and ATR/p-ATR in K562 cells. The results of the present study demonstrated that cyclin A and CDK2 expression were significantly reduced by chaetominine compared with the control (Fig. 4B) . In addition, K562 cells expressed significantly higher levels of Chk1 (P<0.05 at 10, 20 and 40 µM) and Chk2 (P<0.05 at 40 µM) following treatment with chaetominine compared with the control (Fig. 4C) . Furthermore, a detectable alteration in Chk2 levels was only observed following 40 nM chaetominine treatment, while the expression of Chk1 changed significantly even at the lowest concentration (10 nM) of chaetominine (Fig. 4C) . Chk1 protein levels were 5.7-fold greater following 40 nM chaetominine treatment compared with controls, while the Chk2 protein levels had increased by 1.5-fold when the same treatment was applied. The level of cdc25A was marginally attenuated following 40 nM chaetominine treatment (to ~50% that of the control group; Fig. 4C ). The results of the present study suggest that an elevation in p-ATR expression occurred following treatment with chaetominine. These results suggest that chaetominine treatment upregulated p-ATR and Chk1 protein levels and downregulated cdc25A, cyclin A and CDK2, and these proteins are reported to participate in the initiation of S-phase arrest (14, 15) .
Chaetominine treatment affects cell cycle regulator cyclin A/E and CDK2/4 mRNA levels.
To assess the role of direct regulators of cell cycle arrest in K562 and SW1116 cells, the mRNA levels of specific genes were determined using RT-qPCR. The results demonstrated that the mRNA levels of cyclin A and CDK2 in K562 cells were significantly decreased following incubation with 40 nM chaetominine (Fig. 5) . However, minimal changes in the mRNA levels of cyclin E or CDK4 were observed, when compared with the control groups. These results are consistent with the cyclin A and CDK2 expression variation trends observed in chaetominine-treated K562 cells in the present study. Conversely, chaetominine resulted in the downregulation of cyclin E, CDK2 and CDK4 in SW1116 cells. However, the same effect was not observed in cyclin A. These results suggested that chaetominine treatment altered the mRNA levels of cyclin E, CDK2 and CDK4 in SW1116 cells as described in Fig. 6 .
Discussion
Among natural anti-cancer alkaloids, those derived from marine metabolites and their derivatives may be a vital resource for chemotherapeutic discovery due to a low effective dosage and increased selectivity (2, 16) . Previous studies pertaining to these benefits have served a crucial role in the investigation of anticancer candidates in natural products. To further aid in these investigations, the present study utilized the fungal metabolite chaetominine isolated from a culture of Aspergillus fumigatus CY018 (3). This compound exhibited cytotoxic effects in two human cancer cell lines (K562 and SW1116 cells) when used in nanomolar concentrations. However, the effects of chaetominine on the regulation of the cell cycle, which is an important component involved in controlling cellular proliferation, are not well understood. The current study was performed to investigate the relative contribution of chaetominine to the molecular mechanisms associated with cell cycle regulation in K562 and SW1116 cells.
The present study determined that chaetominine markedly inhibited cell growth in K562 (IC 50 ; 34 nM) and SW1116 (IC 50 ; 46 nM) cells. These results are consistent with those of previous studies, which indicated that chaetominine may be a candidate for anti-cancer treatment (11, 15) . The results of the present study, including the dose-dependent increase in apoptosis rate and a sub-G 1 peak in the SW1116 cells treated with 40 nM chaetominine for 24 h, demonstrate that the cytotoxic role of chaetominine in SW1116 and K562 cells is associated with the induction of apoptosis. However, no obvious sub-G 1 peak following exposure to higher concentrations of chaetominine resulted in an inability to collect all the fragments released by dead cells. The cell cycle is an important regulatory mechanism associated with cell growth and proliferation (7, 8) . A variety of anti-cancer agents target the abnormal growth of cells by disrupting cell cycle progression and/or inducing apoptosis (5) . In the present study, SW1116 cells underwent G 1 -phase cell cycle arrest, while K562 cells underwent S-phase arrest following chaetominine treatment. These results suggest that the role of chaetominine in cancer cell death is dependent on cell cycle arrest and apoptosis.
Cyclins and CDKs have been demonstrated to function in the direct regulation of the cell cycle (9) . RT-qPCR analysis utilized in the present study demonstrated that chaetominine-induced cell cycle arrest in K562 cells was associated with the downregulation of cyclin A and CDK2. In SW1116 cells, this occurrence was accompanied by a decrease in cyclin E, CDK2, and to a lesser extent, CDK4. CDK2 activity is restricted to the G 1 -S phase of the cell cycle and results in the binding of different cyclin partners. Cyclin E/CDK2 and CDK4 are recruited for the transition from the G1-phase to the S phase, while cyclin A/CDK2 is utilized for progression through the S-phase. Cyclin A and cyclin E overexpression is commonly observed in leukemia and colon cancer cells, respectively (14) . This overexpression may be indicative of the different types of cell cycle arrest observed in the two cancer cell lines utilized in the present study following treatment with chaetominine. Further studies are required to elucidate whether chaetominine acts as a pharmacological inhibitor of CDKs, with a potent anti-cancer activity.
Cell cycle checkpoint pathways are crucial regulatory machineries involved in the determination of cellular responses to cancer therapy (8) . ATM/Chk2 and ATR/Chk1 signaling modules are involved in the control of checkpoint networks and promote delays in the cell cycle at the G 1 , S or G 2 phase (7, 13) . p53 is a key substrate of the ATM/Chk2 module and also acts as a pro-apoptotic protein (17) . The accumulation of p53 results in the activation of p21, which inactivates the cyclin E/CDK2 complex, subsequently leading to G 1 -phase arrest. This is consistent with results of the present study. It was demonstrated that SW1116 cells expressed higher levels of p-ATM, Chk2, p53 and p21 following chaetominine treatment and that these molecules were important mediators in the arrest of cells at the G 1 -phase (13, 18) . The ATR/Chk2 module elicits its effects following an increase in Chk2 activity, which causes the attenuation of cdc25, cyclin A and CDK2, thus leading to S-phase blockade (19) . In K562 cells, these effects resulted in an increase in the expression of p-ATR and Chk2 following incubation with chaetominine. Conversely, the protein level of cdc25A, cyclin A and CDK2 # P<0.05 vs. CDK2 controls. (C) Protein levels following western blotting using antibodies against ATR, p-ATR (Ser428), Chk1, Chk2 and cdc25A in K562 cells. The bar graphs represent a densitometric analysis conducted to determine protein expression relative to the internal reference protein, GAPDH. Representative blots from three independent experiments are presented and data are presented as the mean ± standard deviation (n=3). * P<0.05 vs. respective control group. ATM, ataxia telangiectasia mutated; ATR, ATM and Rad3-related; p-ATR, phosphorylated ATR; CDK2, cyclin-dependent kinase 2; Chk, checkpoint kinase; cdc25A, cell division cycle 25A. decreased in chaetominine-treated K562 cells. However, Chk1 protein levels remained relatively stable following incubation with the same compound. These results are consistent with those of the present study, suggesting that chaetominine affected the ATR-Chk2-cdc25A-cyclin A/CDK2 signaling pathway. This also occurred independently of p53, facilitating the occurrence of cell cycle arrest during the S-phase (17, 19) .
In conclusion, the present study demonstrated that chaetominine causes the inhibition of cell growth through apoptosis and cell cycle arrest in K562 and SW1116 cells. The current study also revealed the mechanism of action that underpins cell cycle arrest following chaetominine treatment. However, it remains unclear whether the cellular response to chaetominine is actually associated with DNA damage caused by ATM or ATR signal initiation (20) . Furthermore, all of the experiments conducted in the present study were performed in vitro. Further in vivo studies are therefore required to fully characterize the effects associated with this compound. Nevertheless, chaetominine may serve as an important chemotherapeutic agent with several putative clinical applications. State Key Laboratory of Bioreactor Engineering (grant no. 2060204).
